Welcome back to, TIME's new twice-weekly newsletter about AI. If you're reading this in your browser, why not subscribe to have the next one delivered straight to your inbox? We hear a lot about how AI is accelerating drug discovery. But the number of drugs approved by the FDA has remained constant through the AI revolution, at around 50 per year. "The biggest problem in bringing new medicine to patients hasn't been drug discovery for a long time," says Ben Liu, the founder and CEO of Formation Bio, an AI company working in the biotech space.

This moment is a crucial test for Anthropic, a company that claims it can mitigate AI's dangers while still competing in the market. Claude is a direct competitor to ChatGPT, and brings in over 2 billion in annualized revenue. Anthropic argues that its RSP thus creates an economic incentive for itself to build safety measures in time, lest it lose customers as a result of being prevented from releasing new models. "We really don't want to impact customers," Kaplan told TIME earlier in May while Anthropic was finalizing its safety measures. "We're trying to be proactively prepared." But Anthropic's RSP--and similar commitments adopted by other AI companies--are all voluntary policies that could be changed or cast aside at will.